LANA-1, Bcl-2, Mcl-1 and HIF-1α protein expression in HIV-associated Kaposi sarcoma

被引:14
|
作者
Long, E. [1 ]
Ilie, M. [1 ]
Hofman, V. [1 ,2 ,3 ]
Havet, K. [1 ]
Selva, E. [3 ]
Butori, C. [1 ,2 ,3 ]
Lacour, J. P. [4 ]
Nelson, A. M. [5 ]
Cathomas, G. [6 ]
Hofman, P. [1 ,2 ,3 ]
机构
[1] Hop Louis Pasteur, Lab Clin & Expt Pathol, F-06002 Nice, France
[2] INSERM, ERI 21, EA 4319, Nice, France
[3] INSERM, CRB, Human Tissue Biobank Unit, Nice, France
[4] Univ Nice Sophia Antipolis, Dept Dermatol, F-06002 Nice, France
[5] Armed Forces Inst Pathol, Washington, DC 20306 USA
[6] Inst Infect Pathol, Liestal, Switzerland
关键词
HIV; Kaposi sarcoma; LANA-1; Apoptosis; Hypoxia; Tumour progression; ACTIVE ANTIRETROVIRAL THERAPY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HYPOXIA-INDUCIBLE FACTORS; HHV8 ASSOCIATED DISEASES; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; EFFUSION LYMPHOMA; REGULATORY FACTOR; AUTOPSY FINDINGS; HUMAN-HERPESVIRUS-8;
D O I
10.1007/s00428-009-0791-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Human herpesvirus 8 (HHV8) is necessary for Kaposi sarcoma (KS) to develop, but whether the tissue viral load is a marker of KS progression is still unclear. Little is known about the level of expression of apoptosis-regulating proteins and of hypoxia-inducible factors (HIFs) in KS tumour cells relative to HHV8 expression. We therefore investigated the expression of the latency-associated nuclear antigen (LANA-1) of HHV8, Bcl-2, Mcl-1, Bax, Bcl-xL, caspase 3 and HIF-1 alpha in KS tissue specimens at different stages of the disease. The expression of these proteins was evaluated immunohistochemically using tissue microarrays (TMAs) in tissue specimens from 245 HIV-positive patients at different stages of the disease. Both LANA-1 and HIF-1 alpha were expressed in KS biopsies taken at different stages, but their level increased throughout tumour progression. Additionally, the levels of Bcl-2 and Mcl-1 were higher in visceral KS lesions compared to levels observed in cutaneous and mucosal KS. This study demonstrates that late tumour stages of KS in tissues from HIV-positive patients are associated with high levels of LANA-1, HIF-1 alpha and of the anti-apoptotic proteins, Bcl-2 and Mcl-1. Finally, the expression of these proteins can be potentially used as a tissue biomarker in defining patients with a higher risk of disease progression.
引用
收藏
页码:159 / 170
页数:12
相关论文
共 50 条
  • [41] Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
    Morales, Alejo A.
    Kurtoglu, Metin
    Matulis, Shannon M.
    Liu, Jiangxia
    Siefker, David
    Gutman, Delia M.
    Kaufman, Jonathan L.
    Lee, Kelvin P.
    Lonial, Sagar
    Boise, Lawrence H.
    BLOOD, 2011, 118 (05) : 1329 - 1339
  • [42] Immunohistochemical analysis of Bcl-2, Bax, Mcl-1, and Bcl-X expression in ovarian surface epithelial tumours
    Wehrli, BM
    Krajewski, S
    Gascoyne, R
    Reed, JC
    Gilks, CB
    MODERN PATHOLOGY, 1998, 11 (01) : 116A - 116A
  • [43] Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors
    Wehrli, BM
    Krajewski, S
    Gascoyne, RD
    Reed, JC
    Gilks, CB
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1998, 17 (03) : 255 - 260
  • [44] Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bar in malignant mesothelioma
    Soini, Y
    Kinnula, V
    Kaarteenaho-Wiik, R
    Kurttila, E
    Linnainmaa, K
    Pääkkö, P
    CLINICAL CANCER RESEARCH, 1999, 5 (11) : 3508 - 3515
  • [45] The expression of antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1 in benign, dysplastic, and malignant biliary epithelium
    Okaro, AC
    Deery, AR
    Hutchins, RR
    Davidson, BR
    JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (12) : 927 - 932
  • [46] Human eosinophils express Bcl-2 family proteins:: Modulation of Mcl-1 expression by IFN-γ
    Druilhe, A
    Arock, M
    Le Goff, L
    Pretolani, M
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 18 (03) : 315 - 322
  • [47] Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
    Punnoose, Elizabeth A.
    Leverson, Joel D.
    Peale, Franklin
    Boghaert, Erwin R.
    Belmont, Lisa D.
    Tan, Nguyen
    Young, Amy
    Mitten, Michael
    Ingalla, Ellen
    Darbonne, Walter C.
    Oleksijew, Anatol
    Tapang, Paul
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Maiga, Sophie
    Fairbrother, Wayne J.
    Amiot, Martine
    Souers, Andrew J.
    Sampath, Deepak
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1132 - 1144
  • [48] The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients
    Andersen, MH
    Becker, JC
    Straten, PT
    LEUKEMIA, 2005, 19 (03) : 484 - 485
  • [49] Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
    Moujalled, Donia M.
    Hanna, Diane T.
    Hediyeh-zadeh, Soroor
    Pomilio, Giovanna
    Brown, Lauren
    Litalien, Veronique
    Bartolo, Ray
    Fleming, Shaun
    Chanrion, Maia
    Banquet, Sebastien
    Maragno, Ana-Leticia
    Kraus-Berthier, Laurence
    Schoumacher, Marie
    Mullighan, Charles G.
    Georgiou, Angela
    White, Christine A.
    Lessene, Guillaume
    Huang, David C. S.
    Roberts, Andrew W.
    Geneste, Olivier
    Rasmussen, Lorna
    Davis, Melissa J.
    Ekert, Paul G.
    Wei, Andrew
    Ng, Ashley P.
    Khaw, Seong L.
    BLOOD ADVANCES, 2020, 4 (12) : 2762 - 2767
  • [50] Prospects for Drug Designing: Similar Conserved Interactions of Bim with MCL-1 AND BCL-2
    Gupta, Deepti
    Kumar, Amit
    HELIX, 2013, 4 : 357 - 360